Skip to main content

Oncolytics Bio(ONC-T)
TSX

Today's Change
Real-Time Last Update

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

Newswire.ca - Wed Feb 14, 6:00AM CST

Successful Stage 1 data showed a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response, and supports expansion

Read more at newswire.ca

Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe